You are here: Industry Insights > ruxolitinib

News List

Topical JAK inhibitors becoming a major force in atopic dermatitis space: GlobalData expresspharma
July 05, 2021
An increasing number of JAK agents are filling the early and late-stage pipeline. Of the 98 pipeline agents, eight are JAKs – with six of these being topical formulations.
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis drugs
June 21, 2021
Incyte Corporation (Nasdaq:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic dermatitis (AD).
Ruxolitinib (Jakafi) does not prevent complications due to COVID-19 associated cytokine storm: Study expresspharma
December 15, 2020
Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did ...
Ruxolitinib to be studied as COVID-19 treatment in clinical trial europeanpharmaceuticalreview
June 24, 2020
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
Incyte begins Phase III trial of ruxolitinib to treat Covid-19 pharmaceutical-technology
April 21, 2020
Incyte has started a Phase III clinical trial of ruxolitinib (Jakafi) to treat cytokine storm caused by Covid-19 coronavirus infection.